Dr Erica Chen

Research | Current

Development of light-controlled pore-regulated mesoporous silica microparticles which can be activated for drug release by using different wavelength of light

Postgraduate supervision

  • “Ultrasound-mediated delivery of hyaluronan modified connexin43 mimetic peptide loaded human serum albumin nanoparticles in the treatment of diabetic retinopathy”, Di Huang, MSc, The University of Auckland, 2015

Selected publications and creative works (Research Outputs)

  • Huang, D., Chen, Y., Thakur, S., & Rupenthal, I. (2017). Ultrasound-mediated nanoparticle delivery across ex vivo bovine retina after intravitreal injection. European Journal of Pharmaceutics and Biopharmaceutics, 119, 125-136. 10.1016/j.ejpb.2017.06.009
    URL: http://hdl.handle.net/2292/35062
    Other University of Auckland co-authors: Di Huang, Ilva Rupenthal, Sachin Thakur
  • Huang, D., Chen, Y.-S., & Rupenthal, I. D. (2017). Hyaluronic Acid Coated Albumin Nanoparticles for Targeted Peptide Delivery to the Retina. Molecular Pharmaceutics, 14 (2), 533-545. 10.1021/acs.molpharmaceut.6b01029
    URL: http://hdl.handle.net/2292/33406
    Other University of Auckland co-authors: Ilva Rupenthal, Di Huang
  • Huang, D., Chen, Y. S., & Rupenthal, I. (2017). Overcoming ocular drug delivery barriers through the use of physical forces. Advanced Drug Delivery Reviews10.1016/j.addr.2017.09.008
    Other University of Auckland co-authors: Di Huang, Ilva Rupenthal
  • Bisht, R., Jaiswal, J. K., Chen, Y. S., Jin, J., & Rupenthal, I. D. (2016). Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye. Expert Opinion on Drug Delivery, 13 (7), 953-962. 10.1517/17425247.2016.1163334
    URL: http://hdl.handle.net/2292/29334
    Other University of Auckland co-authors: Rohit Bisht, Ilva Rupenthal, Jianyong Jin, Jagdish Jaiswal
  • Chen, Y.-S., Green, C. R., Teague, R., Perrett, J., Danesh-Meyer, H. V., Toth, I., & Rupenthal, I. D. (2015). Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia. Drug delivery and translational research, 5 (5), 480-488. 10.1007/s13346-015-0249-8
    Other University of Auckland co-authors: Ilva Rupenthal, Colin Green, Helen Danesh-Meyer
  • Chen, Y. S., Green, C. R., Danesh-Meyer, H. V., & Rupenthal, I. D. (2015). Neuroprotection in the treatment of glaucoma - A focus on connexin43 gap junction channel blockers. European Journal of Pharmaceutics and Biopharmaceutics, 95, 182-193. 10.1016/j.ejpb.2015.01.031
    Other University of Auckland co-authors: Ilva Rupenthal, Helen Danesh-Meyer
  • Chen, Y. S., Green, C. R., Wang, K., Danesh-Meyer, H. V., & Rupenthal, I. D. (2015). Sustained intravitreal delivery of connexin43 mimetic peptide by poly(d,l-lactide-co-glycolide) acid micro- and nanoparticles - Closing the gap in retinal ischaemia. European Journal of Pharmaceutics and Biopharmaceutics, 95, 378-386. 10.1016/j.ejpb.2014.12.005
    Other University of Auckland co-authors: Helen Danesh-Meyer, Ilva Rupenthal
  • Rupenthal, I. D., Chen, Y. S., Teague, R., Perret, J., Danesh-Meyer, HV, Toth, I., & Green, CR (2013). Modified connexin43 mimetic peptide shows higher efficacy in reducing retinal ganglion cell loss and vessel leak after retinal ischemia. Paper presented at European Association for Vision and Eye Research Conference 2013, Nice, France. 18 September - 21 September 2013. Acta Ophthalmologica Volume 91 supplement s252. (pp. 1). 10.1111/j.1755-3768.2013.1744.x
    Other University of Auckland co-authors: Ilva Rupenthal, Colin Green, Helen Danesh-Meyer

Contact details

Office hours

9am-5pm

Primary location

M&HS BUILDING 504 - Bldg 504
Level 4, Room 441
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand